{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T04:06:03Z","timestamp":1648699563178},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1097\/ico.0000000000000098","type":"journal-article","created":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T17:48:08Z","timestamp":1395078488000},"page":"457-462","source":"Crossref","is-referenced-by-count":2,"title":["Safety of Besifloxacin Ophthalmic Suspension 0.6% in Cataract and LASIK Surgery Patients"],"prefix":"10.1097","volume":"33","author":[{"given":"Parag A.","family":"Majmudar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Clinch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R3-5-20210204","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jac\/dkq127","article-title":". Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.","volume":"65","author":"Haas","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"R4-5-20210204","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/jac\/dkq531","article-title":". In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride.","volume":"66","author":"Haas","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"R5-5-20210204","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1128\/AAC.00418-09","article-title":". Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.","volume":"53","author":"Haas","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-5-20210204","first-page":"3","article-title":"Clinical development of 1 azithromycin in DuraSite, a topical azalide anti-infective for ocular surface therapy.","volume":"1","author":"Friedlaender","year":"2007","journal-title":"Clin Ophthalmol"},{"key":"R7-5-20210204","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/jop.2008.0066","article-title":". Development of a topical polymeric mucoadhesive ocular delivery system for azithromycin.","volume":"25","author":"Bowman","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"key":"R8-5-20210204","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/jop.2009.0026","article-title":". Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1 azithromycin formulation.","volume":"25","author":"Akpek","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"key":"R9-5-20210204","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/jop.2010.0103","article-title":"Pharmacokinetic comparisons of bromfenac in DuraSite and Xibrom.","volume":"27","author":"Si","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"R11-5-20210204","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ophtha.2006.08.038","article-title":". Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case series.","volume":"114","author":"Moshirfar","year":"2007","journal-title":"Ophthalmology"},{"key":"R12-5-20210204","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1089\/jop.2005.21.236","article-title":"A comparison of therapeutic regimens containing moxifloxacin 0.5 ophthalmic solution and gatifloxacin 0.3 ophthalmic solution for surgical prophylaxis in patients undergoing LASIK or LASEK.","volume":"21","author":"Durrie","year":"2005","journal-title":"J Ocul Pharmacol Ther"},{"key":"R13-5-20210204","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jcrs.2008.05.045","article-title":". Third and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years.","volume":"34","author":"Jensen","year":"2008","journal-title":"J Cataract Refract Surg"},{"key":"R14-5-20210204","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1016\/j.jcrs.2007.07.009","article-title":". Prophylaxis of postoperative endophthalmitis after cataract surgery: results of the 2007 ASCRS member survey.","volume":"33","author":"Chang","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"R15-5-20210204","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2011.11.023","article-title":". Postcataract surgery endophthalmitis in the United States: analysis of the complete 2003 to 2004 Medicare database of cataract surgeries.","volume":"119","author":"Keay","year":"2012","journal-title":"Ophthalmology"},{"key":"R16-5-20210204","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ophtha.2009.07.011","article-title":". Infectious keratitis in 204 586 LASIK procedures.","volume":"117","author":"Llovet","year":"2010","journal-title":"Ophthalmology"},{"key":"R17-5-20210204","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2147\/OPTH.S29604","article-title":". Safety of besifloxacin ophthalmic suspension 0.6 as a prophylactic antibiotic following routine cataract surgery: results of a prospective, parallel-group, investigator-masked study.","volume":"6","author":"Malhotra","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"R18-5-20210204","first-page":"149","article-title":"Safety of besifloxacin ophthalmic suspension 0.6 in refractive surgery: a retrospective chart review of post-LASIK patients.","volume":"7","author":"Nielsen","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"R19-5-20210204","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jcrs.2012.08.032","article-title":"Safety of besifloxacin ophthalmic suspension 0.6 in cataract surgery patients.","volume":"38","author":"Parekh","year":"2012","journal-title":"J Cataract Refract Surg"},{"key":"R20-5-20210204","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jcrs.2011.06.038","article-title":". Toxicity comparison of intraocular azithromycin with and without a bioadhesive delivery system in rabbit eyes.","volume":"38","author":"Goecks","year":"2012","journal-title":"J Cataract Refract Surg"},{"key":"R21-5-20210204","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ajo.2010.05.006","article-title":". An anterior chamber toxicity study evaluating Besivance, AzaSite, and Ciprofloxacin.","volume":"150","author":"Ness","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R22-5-20210204","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jcrs.2011.10.040","article-title":". Safety of repeated topical ocular administration of a polycarbophil-based formulation in several models of ocular surgery in rabbits.","volume":"38","author":"Krenzer","year":"2012","journal-title":"J Cataract Refract Surg"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICO.0000000000000098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:08:47Z","timestamp":1620954527000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003226-201405000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0000000000000098","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}